Table 2.
Comparison of laboratory data of patients with TBEV infection (TBE) and TBEV+Bb/Ap co-infection (TBE+LD/HGA1) as well as therapy (TBE2 and TBE+LD/HGA2) compared to healthy subjects.
| Normal Range | TBE | TBEV+Bb/Ap | |||
|---|---|---|---|---|---|
| At Admission | After Recovery | At Admission | After Recovery | ||
| Complete blood count | |||||
| WBC [103/μL] | 4.00–10.00 | 10.16 ± 2.37 | 6.11 ± 1.48 | 7.27 ± 1.36 | 5.37 ± 1.46 |
| Neutrophils [%] | 40.0–72.0 | 73.77 ± 9.52 | 51.18 ± 7.93 | 60.33 ± 7.07 | 42.58 ± 11.58 |
| Lymphocytes [%] | 18.00–48.00 | 16.2 ± 7.76 | 34.83 ± 6.35 | 27.37 ± 6.11 | 42.72 ± 11.24 |
| Monocytes [%] | 2.50–10.00 | 8.99 ± 2.53 | 9.79 ± 2.15 | 10.15 ± 2.61 | 9.56 ± 3.18 |
| RBC [106/μL] | 4.00–5.50 | 4.40 ± 0.43 | 4.50 ± 0.32 | 4.28 ± 0.56 | 4.14 ± 0.62 |
| HGB [g/dL] | 12.00–16.00 | 13.32 ± 1.28 | 13.68 ± 1.09 | 12.67 ± 1.26 | 12.5 ± 1.39 |
| PLT [103/μL] | 130–350 | 251.44 ± 87.43 | 270.59 ± 134.4 | 262.67 ± 66.98 | 218.4 ± 19.42 |
| CRP [mg/L] | 0.00–5.00 | 11.52 ± 15.61 | 0.93 ± 0.54 | 2.35 ± 2.08 | 0.81 ± 0.26 |
| Glucose [mg/dL] | 70–110 | 96.77 ± 10.27 | 89.62 ± 12.1 | 92.67 ± 8.5 | 91.75 ± 5.97 |
| Creatinine [mg/dL] | 0.50–0.90 | 0.88 ± 0.16 | 0.82 ± 0.12 | 0.79 ± 0.08 | 0.76 ± 0.12 |
| ALT [U/I] | 0–31 | 21.10 ± 19.17 | 24.17 ± 17.20 | 17.75 ± 11.27 | 12 ± 5.24 |
| AST [U/I] | 0–32 | 15.59 ± 5.26 | 22.42 ± 9.23 | 17 ± 3.67 | 16.33 ± 3.21 |
| CSF analysis | |||||
| Cytosis [cells/µL] | 0–5 | 169.7 ± 115.64 | 26.90 ± 25.59 | 99 ± 120.57 | 14.8 ± 12.15 |
| Protein [mg/dL] | 15–45 | 75.95 ± 20.56 | 54.46 ± 26.32 | 69 ± 58.49 | 48.2 ± 27.74 |